DB:A8V1

Stock Analysis Report

Executive Summary

Cotinga Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer and other unmet medical needs.

Rewards

Earnings have grown 4.5% per year over the past 5 years

Risk Analysis

Does not have a meaningful market cap (€1M)

Currently unprofitable and not forecast to become profitable over the next 3 years

Has less than 1 year of cash runway

Highly volatile share price over past 3 months

+ 1 more risk


Snowflake Analysis

Weak fundamentals or lack of information.

Share Price & News

How has Cotinga Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: A8V1's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

0%

A8V1

-0.6%

DE Biotechs

-2.4%

DE Market


1 Year Return

-15.6%

A8V1

8.1%

DE Biotechs

11.8%

DE Market

Return vs Industry: A8V1 underperformed the German Biotechs industry which returned 5.3% over the past year.

Return vs Market: A8V1 underperformed the German Market which returned 17.1% over the past year.


Shareholder returns

A8V1IndustryMarket
7 Day0%-0.6%-2.4%
30 Day35.0%-3.7%-1.1%
90 Dayn/a14.7%3.0%
1 Year-15.6%-15.6%8.3%8.1%15.3%11.8%
3 Year-98.7%-98.7%55.6%53.8%14.4%4.4%
5 Yearn/a16.3%13.8%23.8%7.0%

Price Volatility Vs. Market

How volatile is Cotinga Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Cotinga Pharmaceuticals undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Cotinga Pharmaceuticals is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Cotinga Pharmaceuticals has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of A8V1’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Cotinga Pharmaceuticals regulatory filings.
  • Explore potentially undervalued companies in the Pharmaceuticals & Biotech industry.

Future Growth

How is Cotinga Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

40.0%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Cotinga Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Cotinga Pharmaceuticals performed over the past 5 years?

4.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: A8V1 is currently unprofitable.

Growing Profit Margin: A8V1 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: A8V1 is unprofitable, but has reduced losses over the past 5 years at a rate of 4.5% per year.

Accelerating Growth: Unable to compare A8V1's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: A8V1 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (5.4%).


Return on Equity

High ROE: A8V1's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Cotinga Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: A8V1 has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: A8V1 has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: A8V1 has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: A8V1's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet

Inventory Level: A8V1 has a low level of unsold assets or inventory.

Debt Coverage by Assets: A8V1 has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: A8V1 has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if A8V1 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Cotinga Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.6%industryaverage1.0%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate A8V1's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate A8V1's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if A8V1's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if A8V1's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of A8V1's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

What is the CEO of Cotinga Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

2.8yrs

Average management tenure


CEO

Alison Silva 0

3yrs

Tenure

CA$549,946

Compensation

Ms. Alison D. Silva, MA, MS, has been the Chief Executive Officer, President and Consultant of Critical Outcome Technologies Inc. since January 1, 2017, July 5, 2016 and 2013 respectively. Ms. Silva founde ...


CEO Compensation Analysis

Compensation vs Market: Alison's total compensation ($USD0.00) is below average for companies of similar size in the German market ($USD425.50K).

Compensation vs Earnings: Alison's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

2.8yrs

Average Tenure

Experienced Management: A8V1's management team is considered experienced (2.8 years average tenure).


Board Age and Tenure

4.8yrs

Average Tenure

69yo

Average Age

Experienced Board: A8V1's board of directors are considered experienced (4.8 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Buy€3,83029 Jan 19
John Drake
EntityIndividual
Role
Chairman of the Board
Independent Chairman of the Board
Shares241,000
Max Price€0.016

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 14.2%.


Management Team

  • Alison Silva

    CEO, President & Director

    • Tenure: 3yrs
    • Compensation: CA$549.95k
  • Richard Ho (56yo)

    Chief Scientific Officer

    • Tenure: 2.6yrs
    • Compensation: CA$323.16k
  • Debi Sanderson

    Director of Resourcing & Operations

    • Tenure: 3yrs
  • Paul Papi

    Vice President of Investor Relations

    • Vic Hugo (51yo)

      Chief Financial Officer

      • Tenure: 0.3yrs

    Board Members

    • Nancy Chang (69yo)

      Member of Scientific Advisory Board

      • Tenure: 3.8yrs
    • David Parkinson (69yo)

      Member of Scientific Advisory Board

      • Tenure: 4.8yrs
    • Matt Bond (58yo)

      Independent Director

      • Tenure: 1.5yrs
    • Gordon Mills

      Member of Scientific Advisory Board

      • Tenure: 4.8yrs
    • John Drake (71yo)

      Independent Chairman of the Board

      • Tenure: 12.8yrs
      • Compensation: CA$17.57k
    • Alison Silva

      CEO, President & Director

      • Tenure: 3yrs
      • Compensation: CA$549.95k
    • Dave Sanderson

      Independent Director

      • Tenure: 6.1yrs
      • Compensation: CA$17.51k
    • Marshall Strome

      Member of Scientific Advisory Board

      • Tenure: 4.8yrs
    • Douglas Levine

      Member of Scientific Advisory Board

      • Tenure: 4.8yrs

    Company Information

    Cotinga Pharmaceuticals Inc.'s company bio, employee growth, exchange listings and data sources


    Key Information

    • Name: Cotinga Pharmaceuticals Inc.
    • Ticker: A8V1
    • Exchange: DB
    • Founded:
    • Industry: Biotechnology
    • Sector: Pharmaceuticals & Biotech
    • Market Cap: CA$1.759m
    • Listing Market Cap: CA$1.211m
    • Shares outstanding: 21.99m
    • Website: https://www.cotingapharma.com

    Number of Employees


    Location

    • Cotinga Pharmaceuticals Inc.
    • The Canadian Venture Building
    • 82 Richmond Street East
    • Toronto
    • Ontario
    • M5C 1P1
    • Canada

    Listings

    TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
    COTTSXV (TSX Venture Exchange)YesCommon SharesCACADOct 2006
    COTQ.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDOct 2006
    A8V1DB (Deutsche Boerse AG)YesCommon SharesDEEUROct 2006

    Biography

    Cotinga Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer and other unmet medical needs. The company’s lead compound is COTI-2, an oral small molecule targeting p53 a tumor suppressor gene. It also develops COTI-219, an oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS functions. Cotinga Pharmaceuticals Inc. has a research collaboration with St. Vincent’s University Hospital to evaluate COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer. The company was formerly known as Critical Outcome Technologies Inc. and changed its name to Cotinga Pharmaceuticals Inc. in January 2018. Cotinga Pharmaceuticals Inc. is based in Toronto, Canada. 


    Company Analysis and Financial Data Status

    All financial data provided by Standard & Poor's Capital IQ.
    DataLast Updated (UTC time)
    Company Analysis2020/01/27 22:49
    End of Day Share Price2020/01/27 00:00
    Earnings2019/10/31
    Annual Earnings2019/04/30


    Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.